221 related articles for article (PubMed ID: 28767200)
1. Correlation between activated partial thromboplastin time and anti-Xa activity in patients who received low-molecular weight heparin as anticoagulation for haemodialysis.
Wong SS; Lau WY; Chan PK; Wan CK; Cheng YL
Nephrology (Carlton); 2017 Nov; 22(11):921-924. PubMed ID: 28767200
[TBL] [Abstract][Full Text] [Related]
2. Practical Value of Anti-Xa Activity in the Evaluation of Extracorporeal Circuit Anticoagulation during Haemodialysis: Results of a Cross-Sectional Single-Centre Study.
Coene KLM; Dekker MJE; Kerskes MCHM; Hengst M; Schonck MJM; Konings CJAM; Scharnhorst V
Nephron; 2017; 137(3):205-211. PubMed ID: 28817831
[TBL] [Abstract][Full Text] [Related]
3. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin in hemodialysis patients with a bleeding tendency.
Leu JG; Chiang SS; Lin SM; Pai JK; Jiang WW
Nephron; 2000 Dec; 86(4):499-501. PubMed ID: 11124600
[TBL] [Abstract][Full Text] [Related]
5. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
6. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
7. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
Janssen MJ; Deegens JK; Kapinga TH; Beukhof JR; Huijgens PC; van Loenen AC; van der Meulen J
Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
[TBL] [Abstract][Full Text] [Related]
8. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
9. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay.
Kostousov V; Nguyen K; Hundalani SG; Teruya J
Arch Pathol Lab Med; 2014 Nov; 138(11):1503-6. PubMed ID: 25357112
[TBL] [Abstract][Full Text] [Related]
10. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
[TBL] [Abstract][Full Text] [Related]
11. Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
Oudemans-van Straaten HM; van Schilfgaarde M; Molenaar PJ; Wester JP; Leyte A
Crit Care; 2009; 13(6):R193. PubMed ID: 19958532
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
Rizk E; Wilson AD; Murillo MU; Putney DR
Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
[TBL] [Abstract][Full Text] [Related]
13. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis.
Shinoda T; Arakura H; Katakura M; Shirota T; Nakagawa S
Artif Organs; 1990 Dec; 14(6):413-5. PubMed ID: 2177970
[TBL] [Abstract][Full Text] [Related]
15. Clinical study on low-molecular weight heparin infusion as anticoagulation for nocturnal home haemodialysis.
Wong SS; Lau WY; Ng ML; Chan SY; Chan SF; Chan PK; Wan CK; Cheng YL
Nephrology (Carlton); 2018 Apr; 23(4):317-322. PubMed ID: 28052451
[TBL] [Abstract][Full Text] [Related]
16. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
17. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
Ip BK; Thomson AR; Moriarty HT
Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
[TBL] [Abstract][Full Text] [Related]
19. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
20. Use of viscoelastic coagulation testing to monitor low molecular weight heparin administration to healthy horses.
Tennent-Brown BS; Epstein KL; Whelchel DD; Giguère S
J Vet Emerg Crit Care (San Antonio); 2013; 23(3):291-9. PubMed ID: 23656212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
